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Abstract
An activating point mutation in codon 12 of the HRAS gene was the first somatic point mutation
identified in a human cancer and established the role of somatic mutations as the common driver
of oncogenesis. Since then, there have been over 11,000 mutations in the three RAS (HRAS,
KRAS and NRAS) genes in codons 12, 13 and 61 reported in the literature. We report here the
identification of recurrent somatic missense mutations at alanine 146, a highly conserved residue
in the guanine nucleotide binding domain. In two independent series of colorectal cancers from
Hong Kong and the United States we detected KRAS A146 mutations in 7/126 and 2/94 cases,
respectively, giving a combined frequency of 4%. We also detected KRAS A146 mutations in
2/40 (5%) colorectal cell lines, including the NCI-60 colorectal cancer line HCC2998. Codon 146
mutations thus are likely to make an equal or greater contribution to colorectal cancer than codon
61 mutations (4.2% in our combined series, 1% in the literature). Lung adenocarcinomas and large
cell carcinomas did not show codon 146 mutations. We did, however, identify a KRAS A146
mutation in the ML-2 acute myeloid leukemia cell line and an NRAS A146 mutation in the
NALM-6 B-cell acute lymphoblastic leukemia line, suggesting that the contribution of codon 146
mutations is not entirely restricted to colorectal cancers or to KRAS.
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INTRODUCTION
Somatic mutations in critical target genes are the basic driving force in the development of
cancer. The first somatic point mutation described in human cancer was an activating codon
12 glycine to valine mutation in the HRAS gene present in the EJ/T24 bladder carcinoma
cell line.1,2 The further identification and characterisation of somatic mutations from the
full spectrum of human cancers has been a major focus of cancer research in the ensuing 25
years.
To date, over 11,000 point mutations in codons 12, 13 and 61 have been reported in the
HRAS, NRAS and KRAS genes combined (www.sanger.ac.uk/genetics/CGP/cosmic). The
three RAS genes encode 21 kilodalton proteins with intrinsic GTPase activity which cycle
between a GDP-bound “off” form and a GTP-bound “on” form. These alternate forms are
regulated by GAPs (GTPase activating proteins) and GEFs (guanine nucleotide exchange
factors), respectively. RAS proteins are involved in coupling signal transduction from cell
surface receptors to cytoplasmic targets and mediating a variety of cellular responses
including proliferation, cytoskeletal reorganisation and survival pathways. Activating
mutations stabilise or otherwise promote a preponderance of the GTP-bound “on” form, thus
inappropriately affecting downstream activities.
The KRAS gene is mutated in over 30% of colorectal cancers. There have been
approximately 3000 KRAS point mutations in colorectal cancer reported in the literature
(www.sanger.ac.uk/genetics/CGP/cosmic/). The majority (~82%) of reported mutations are
in codon 12. Mutations at codons 13 and 61 contribute to a lesser degree, accounting for
~17% and ~1% respectively. We report here the identification of recurrent mutations at
codon 146 in KRAS in colorectal cancers, indicating that mutations at this codon are making
a heretofore unappreciated contribution to human neoplasia.
MATERIALS AND METHODS
The collection of all patient materials and their use in the current study were approved by
appropriate local Institutional/ethical Review Board. Genomic DNA was extracted from
tumour and paired normal tissues as previously described.3 The Johns Hopkins University
colorectal cancer sample series was carried as early passage cell lines or xenografts as
described previously.4 PCR amplification and direct sequencing of KRAS using fluorescent
dideoxy sequencing on ABI-3730 sequencers was done as previously described5 using the
following primers flanking all four coding exons of KRAS (isoform b, accession GI:
34485723 NM_004985): exon 2:F-GTGTGACATGTTCTAATATAGTCA, R-
GAATGGTCCTGCACCAGTAA; exon 3:F-TCAAGTCCTTTGCCCATTTT, R-
TGCATGGCATTAGCAAAGAC exon 4: F-GAAACCAAAGCCAAAAGCAG, R-
AGTAGAAGAAGGAAGGAAAATTTGG; exon 5: F-
TGGGAATACTGGCACTTAGAGG, R-TTGACAAAACACCTATGCGG.
Sequence data was analysed using semi-automated analysis using Mutation Surveyor and in-
house software coupled with manual inspection of potentially mutant traces followed by a
manual rescoring of all sequence traces.
STATISTICAL METHODS
Differences in the relative incidences of KRAS mutations in codons 12, 13, 61 and 146,
between tissue types, were assessed by first computing a chi-squared statistic based on the
contingency table of mutation counts by codon and type. The significance of this statistic
was evaluated by Monte Carlo simulation, using 10,000 simulations of the data under the
null hypothesis of no difference in the relative incidence of codons, conditional on the
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number of mutations in each codon group and the total number of mutations of each type.
This provides an exact statistic, necessary for contingency tables containing low counts.
RESULTS
Coding exons of the KRAS gene were resequenced in a series of 126 primary colorectal
cancer cases (CRC) from Hong Kong. Recurrent point mutations resulting in amino acid
substitutions of alanine 146 were identified in seven cases (Table 1 and Fig. 1). Further
screening in an additional series of 94 colorectal cancer samples from the United States
yielded two further codon 146 mutations. All of these codon 146 mutations from cancers
were demonstrated to be somatic by analysis of normal DNA from the same individuals.
Two additional codon 146 mutations were detected in 40 colorectal cancer cell lines (Tables
1 and 2). However, normal DNAs from these individuals were not available to confirm their
somatic origin. Combining colorectal cancer primary tumor, xenograft and cell line data, 11
mutations (Table 1) were identified: 8 c.436G>A p.A146T, 2 c.437C>T p.A146V and 1 c.
436G>C p.A146P. A set of 94 sporadic colorectal adenomas were screened in addition and
no instances of A146 mutation were identified. Full frequency and distribution data for
KRAS mutations in the colorectal screens are shown in Table 3. In addition, a series of 63
adenomas from familial adenomatous polyposis patients and 34 hyperplastic colorectal
polyps where both KRAS and BRAF have previously6 been shown to play a role were also
screened but no A146 mutations were identified (data not shown). Further screening of all
three RAS genes in series of ~700 cancer cell lines revealed two additional A146 mutations:
a KRAS c.436G>A p.A146T in the ML-2 acute myeloid leukemia cell line and a c.436G>A
p.A146T in NRAS in the NALM-6 B-cell acute lymphoblastic leukemia cell line (Table 1).
The distribution of KRAS mutant alleles was different between CRC from Hong Kong and
United States (p = 0.0306). This was primarily due to a difference in relative mutation
prevalence between codons 12 and 13 which has been noted previously.7 However, a higher
proportion of A146 mutations in Hong Kong compared to US CRC also contributed to the
difference between the two series and larger genetic epidemiological studies are warranted
to determine if this A146 trend is reproducible. Overall, KRAS A146 mutations were
detected in 4% (11/260) of CRC and accounted for 8% (11/135) of all observed KRAS
mutations. These data suggest that A146 mutations make a larger contribution to colorectal
cancer than Q61 mutations, which accounted for 2% (5/260) of cases in this study and 1% in
the literature (www.sanger.ac.uk/genetics/CGP/cosmic/). Screening for mutations in BRAF
revealed no cases with both A146 and BRAF mutations (data not shown). One primary
tumor (PD1532) had both a heterozygous p.A146V mutation as well as a heterozygous
p.G12V mutation in KRAS. Whether this reflects intratumoral heterogeneity or truly
coincident, presumably biallelic, KRAS activation in the same clone is not known. As this
case is a primary tumour, single-cell cloning experiments are not possible to differentiate the
two possibilities. Further work to determine if biallelic RAS mutations have greater
transforming potential would be of interest.
The contribution of A146 mutations to another cancer type that is driven in large part by
KRAS mutations was investigated by analysing a series of non-small-cell lung cancers
(NSCLC) comprised of adenocarcinomas, bronchioalveolar and large cell undifferentiated
carcinomas in which KRAS mutations are known to be prevalent. In total, 99 primary tumor
and 66 cell lines were sequenced for KRAS. While KRAS codon 12, 13 and 61 mutations
were detected at the expected combined frequency of 33% (55/165), no instances of A146
mutations were detected (p = 0.0305 compared to CRC).
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DISCUSSION
We have identified A146 missense substitutions as a new class of recurrent somatic
mutation in the KRAS gene in colorectal cancers. Data from independent series indicate that
A146 mutations are involved in approximately 4% of colorectal cancers. Extrapolating from
a worldwide CRC incidence of approximately 950,000 cases/year,8 these data suggest there
are approximately 30,000 cases/year of CRC that are KRAS A146 mutant. Additional A146
(both KRAS and NRAS) mutations were detected in leukaemia cell lines, suggesting a role
for A146 alleles in other tumour types. However, we did not detect A146 mutations in a
series of NSCLC where KRAS mutations are also prevlaent. It is possible that the sequence
context of codon 146 (tca GCA146 aag) renders the guanine at codon 146 less susceptible to
adduction by tobacco smoke carcinogens than guanines at codons 12 and 13 (gct GGT12
GGC13 gta). Alternatively, it may be that substitution of serine for alanine at codon 146,
which would require a G>T transversion typical of cigarette smoke polycyclic aromatic
hydrocarbon mutagenesis,9 may not confer transforming activity on KRAS.
To our knowledge there has been no report of recurrent A146 mutations to date and only
two reports of single A146 mutations in human cancer in the literature from over 15 years
ago.10-12 It is remarkable that, despite ~70,000 cancer samples analysed for mutations in
RAS genes over the last 25 years (www.sanger.ac.uk/genetics/CGP/cosmic/), the role of
codon 146 mutations essentially has been overlooked. This reflects a persistent bias in
mutation screening which has been almost exclusively directed at the first two coding exons
of the RAS genes (encoding codons 12,13 and 61). Mutation screening should be extended
to include A146 for all three RAS genes in future.
RAS mutations at alanine 146 have been identified and characterised in experimental
systems twice in the literature. A transforming Kras p.A146T allele was detected in a thymic
lymphoma induced by exposure of mice to an acute whole-body dose of neutron radiation.
13 NIH 3T3 focus-forming assays with tumour DNA from the lymphoma-derived nude
mouse tumours demonstrated transforming capability of the A146T allele, albeit at lower
efficiency than Kras codon 12 and 13 alleles. In an in vitro mutagenesis screen for mutations
that increased guanine nucleotide exchange rates, GTPase activity and transforming
potential in HRAS, a p.A146V mutation was found to have partial transforming activity
which was attributable to >1000-fold increase in the GDP → GTP exchange rate without
affecting the GTPase activity.14 Alanine 146 is within the highly conserved G-5
(aa144-146) region of the protein (Fig. 2) and forms a hydrogen bond with the guanine ring
of GTP.15 Mutations of this residue presumably alter the local structure such that the GTP-
bound state is much favoured over GDP-bound form. Whether this is accomplished by
increased GEF binding or through some other mechanism is unknown. It is likely however
that increased exchange is accounting, at least in part, for the oncogenic properties of A146
mutant alleles.
Various studies in colorectal cancer have suggested that KRAS codon 12 and 13 mutations
are generally predicitve of a poorer prognosis, with evidence being presented for mutation-
specific prognostic as well as histopathology correlates.16-19 The influence of A146 alleles
on clinical outcome and tumour characteristics therefore requires investigation. As well, the
extent to which colorectal cancers harbouring this class of KRAS mutation are more or less
responsive to current therapies needs to be investigated. It has recently been shown that
KRAS mutations are predictive of resistance to treatment with cetuximab in colorectal
cancer.20 This study analysed only mutations in codons 12 and 13 and it is therefore
plausible that a further subset of patients are resistant due to A146 mutations. It will be also
be interesting to assess response of the A146 mutant cancer cell lines detailed here (one of
which, HCC2998 is a component of the NCI-60 series) to various anticancer agents and
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compare these responses to cancer cells that have other RAS and BRAF mutations, as
exemplified by the recently described work on MEK inhibitors.21
In summary, we have demonstrated that KRAS A146 mutations are recurrent in human
colorectal cancers, are more prevalent than Q61 mutations in this cancer type and are thus
making a substantial contribution to colorectal cancer in the population. These findings will
further empower the molecular pathology and clinical investigation of this common tumor
type.
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Figure 1.
Representative sequencing chromatogram of c.436G>A p.A146T KRAS mutation from
primary colorectal tumour PD2032a. The postion of the G>A substitution is indicated by the
crosshairs and red A above the trace.
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Figure 2.
Conservation of alanine 146 in RAS genes. Accession number of sequence and species of
origin/gene are given the left and right of the alignment, respectively. The position of A146
is underlined.
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Table 1
Codon A146 mutations detected
Colorectal Cancers
Gene Sample Mutation
KRAS PD2032a c.436G>A p.A146T
KRAS PD2048a c.436G>A p.A146T
KRAS PD2070a c.436G>A p.A146T
KRAS PD2019a c.436G>A p.A146T
KRAS PD1978a c.436G>C p.A146P
KRAS PD2068a c.437C>T p.A146V
KRAS PD1532a c.437C>T p.A146V
KRAS JHU-1 c.436G>A p.A146T
KRAS JHU-2 c.436G>A p.A146T
Cancer Cell Lines
Gene Sample/Cancer Type Mutation
KRAS HCC2998, CRC c.436G>A p.A146T
KRAS LS1034, CRC c.436G>A p.A146T
KRAS ML-2, AML c.436G>A p.A146T
NRAS NALM-6, B-ALL c.436G>A p.A146T
CRC, colorectal cancer; AML, acute myeloid leukemia; B-ALL- B-cell acute lymphoblastic leukemia.
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Table 2
KRAS mutations in CRC cell lines
CRC Cell Line KRAS mutation Zygosity
C2BBe1 ND -
Car-1 ND -
CoCM-1 ND -
COLO-205 ND -
COLO-320-HSR ND -
COLO-678 c.35G>A p.G12D Het
COLO-741 ND -
CW-2 ND -
DLD-1-JCRB c.38G>A p.G13D Het
ECC4 c.A182A>G p.Q61R Hom
Gp2D c.35G>A p.G12D Het
GP5d c.35G>A p.G12D Het
HCC2998 c.436G>A p.A146T Het
HCT-116 c.38G>A, p.G13D Het
HCT-15 c.38G>A, p.G13D Het
HT-29 ND -
HT55 ND -
KM12 ND -
LoVo c.38G>A p.G13D Het
LS1034 c.436G>A p.A146T Hom
LS-123 c.34G>A p.G12S Het
LS-174T c.35G>A p.G12D Het
LS-411N ND
LS-513 c.35G>A p.G12D Het
NCI-H508 ND -
NCI-H630 ND -
NCI-H716 ND -
NCI-H747 c.38G>A p.G13D Het
RCM-1 c.35G>T p.G12V Hom
RKO ND -
SK-CO1 c.35G>T p.G12V Hom
SNU-C1 ND -
SNU-C2B c.35G>A p.G12D Hom
SW1116 c.G35G>C p.G12A Het
SW1417 ND -
SW1463 c.35G>A p.G12D Hom
SW403 c.35G>T p.G12V Hom
SW48 ND -
SW480 c.35G>T p.G12V Hom
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CRC Cell Line KRAS mutation Zygosity
SW620 c.35G>T p.G12V Hom
SW837 c.G34G>T p.G12C Het
SW948 c.A182A>T p.Q61L Het
T84 c.38G>A p.G13D Het
Het, heterozygous; Hom, homozygous; ND, none detected
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Table 3
KRAS mutation distribution in study sets
HK_CGP CRC JHU CRC
WT 76 WT 29
Codon 12 MUT 24 Codon 12 MUT 46
Codon 13 MUT 18 Codon 13 MUT 15
Codon 61 MUT 1 Codon 61 MUT 2
Codon 146 MUT 7 Codon 146 MUT 2
Total 126 Total 94
CRC Cell Lines HK_CGP sporadic adenoma
WT 19 WT 68
Codon 12 MUT 14 Codon 12 MUT 18
Codon 13 MUT 3 Codon 13 MUT 6
Codon 61 MUT 2 Codon 61 MUT 2
Codon 146 MUT 2 Codon 146 MUT 0
Total 40 Total 94
HK_CGP, Hong Kong, Cancer Genome Project; JHU, Johns Hopkins University; CRC, colorectal cancer.
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